JP7048571B2 - 毒性を予防または改善するための早期介入法 - Google Patents

毒性を予防または改善するための早期介入法 Download PDF

Info

Publication number
JP7048571B2
JP7048571B2 JP2019500746A JP2019500746A JP7048571B2 JP 7048571 B2 JP7048571 B2 JP 7048571B2 JP 2019500746 A JP2019500746 A JP 2019500746A JP 2019500746 A JP2019500746 A JP 2019500746A JP 7048571 B2 JP7048571 B2 JP 7048571B2
Authority
JP
Japan
Prior art keywords
cells
therapy
subject
administration
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509351A (ja
JP2019509351A5 (enExample
Inventor
マイケル イェンセン
レベッカ ガードナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58609964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7048571(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of JP2019509351A publication Critical patent/JP2019509351A/ja
Publication of JP2019509351A5 publication Critical patent/JP2019509351A5/ja
Priority to JP2022047991A priority Critical patent/JP7528143B2/ja
Application granted granted Critical
Publication of JP7048571B2 publication Critical patent/JP7048571B2/ja
Priority to JP2024118592A priority patent/JP2024156736A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019500746A 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法 Active JP7048571B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022047991A JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US62/311,906 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US62/417,287 2016-11-03
US201662429722P 2016-12-02 2016-12-02
US62/429,722 2016-12-02
PCT/US2017/023676 WO2017165571A1 (en) 2016-03-22 2017-03-22 Early intervention methods to prevent or ameliorate toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022047991A Division JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法

Publications (3)

Publication Number Publication Date
JP2019509351A JP2019509351A (ja) 2019-04-04
JP2019509351A5 JP2019509351A5 (enExample) 2020-04-30
JP7048571B2 true JP7048571B2 (ja) 2022-04-05

Family

ID=58609964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019500746A Active JP7048571B2 (ja) 2016-03-22 2017-03-22 毒性を予防または改善するための早期介入法
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022047991A Active JP7528143B2 (ja) 2016-03-22 2022-03-24 毒性を予防または改善するための早期介入法
JP2024118592A Pending JP2024156736A (ja) 2016-03-22 2024-07-24 毒性を予防または改善するための早期介入法

Country Status (13)

Country Link
US (5) US11518814B2 (enExample)
EP (3) EP4015536A1 (enExample)
JP (3) JP7048571B2 (enExample)
KR (1) KR20190021200A (enExample)
CN (1) CN109476743A (enExample)
AU (2) AU2017238218B2 (enExample)
BR (1) BR112018069251A2 (enExample)
CA (1) CA3018588A1 (enExample)
ES (1) ES2907557T3 (enExample)
MA (2) MA44486A (enExample)
MX (1) MX2018011480A (enExample)
RU (1) RU2018136877A (enExample)
WO (1) WO2017165571A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
SG10202104804PA (en) 2014-10-20 2021-06-29 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
ES2901795T3 (es) 2015-12-04 2022-03-23 Juno Therapeutics Inc Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
JP7048571B2 (ja) 2016-03-22 2022-04-05 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 毒性を予防または改善するための早期介入法
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
RU2019120398A (ru) * 2016-12-03 2021-01-12 Джуно Терапьютикс, Инк. Способы определения дозировки cart-клеток
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
CA3053539A1 (en) 2017-02-27 2018-08-30 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019109053A1 (en) * 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
AU2019209432A1 (en) * 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
WO2019170845A1 (en) * 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
CN111989344A (zh) * 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
US20210263045A1 (en) * 2018-04-06 2021-08-26 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
ES2970382T3 (es) * 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Método para bloquear o mejorar el síndrome de liberación de citocinas
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
US20230366893A1 (en) * 2020-09-29 2023-11-16 Washington University Methods to determine risk of neurotoxicity
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
DK4333840T3 (da) 2021-05-03 2025-11-24 Incyte Corp Jak1-vejinhibitorer til behandling af prurigo nodularis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522081A (ja) 2012-07-13 2015-08-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒの抗腫瘍活性のための毒性管理

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2007147623A2 (en) * 2006-06-22 2007-12-27 Cellact Pharma Gmbh A novel target in the treatment of cytokine release syndrome
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
EP3338895B1 (en) 2007-12-07 2022-08-10 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
ES2911246T3 (es) 2009-11-03 2022-05-18 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
CA2810465C (en) * 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2665548C2 (ru) 2012-05-03 2018-08-30 Фред Хатчинсон Кансэр Рисёч Сентер Способ получения клеток, экспрессирующих т-клеточный рецептор
PL2884999T3 (pl) 2012-08-20 2021-07-05 Fred Hutchinson Cancer Research Center Sposób i kompozycje do immunoterapii komórkowej
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
IL303543A (en) * 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
JP7048571B2 (ja) 2016-03-22 2022-04-05 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 毒性を予防または改善するための早期介入法
CN120285179A (zh) 2016-07-15 2025-07-11 诺华股份有限公司 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522081A (ja) 2012-07-13 2015-08-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒの抗腫瘍活性のための毒性管理

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD，2014年，Vol.124, No.2，pp.188-195
Cancer Letters，2014年，Vol.343，pp.172-178
N Engl J Med，2013年，Vol.368，pp.1509-1518
Sci Transl Med，2013年，Vol.5, Issue 177，177ra38, pp.1-9

Also Published As

Publication number Publication date
JP2019509351A (ja) 2019-04-04
EP4015536A1 (en) 2022-06-22
CA3018588A1 (en) 2017-09-28
MA71266A (fr) 2025-04-30
MA44486A (fr) 2019-01-30
ES2907557T3 (es) 2022-04-25
AU2024205049A1 (en) 2024-08-15
EP4545143A2 (en) 2025-04-30
MX2018011480A (es) 2019-03-28
US20230212298A1 (en) 2023-07-06
US12098208B2 (en) 2024-09-24
WO2017165571A1 (en) 2017-09-28
EP4545143A3 (en) 2025-07-23
JP7528143B2 (ja) 2024-08-05
BR112018069251A2 (pt) 2019-01-22
AU2017238218B2 (en) 2024-05-02
JP2022088489A (ja) 2022-06-14
KR20190021200A (ko) 2019-03-05
US20190112379A1 (en) 2019-04-18
US11518814B2 (en) 2022-12-06
US20230322937A1 (en) 2023-10-12
AU2017238218A1 (en) 2018-10-11
RU2018136877A (ru) 2020-04-22
CN109476743A (zh) 2019-03-15
US20230091447A1 (en) 2023-03-23
JP2024156736A (ja) 2024-11-06
US11760804B2 (en) 2023-09-19
US20240425608A1 (en) 2024-12-26
EP3433276B1 (en) 2021-12-22
EP3433276A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
JP7048571B2 (ja) 毒性を予防または改善するための早期介入法
US20230285463A1 (en) Methods and compositions for dosing in adoptive cell therapy
US11815514B2 (en) Methods and compositions related to toxicity associated with cell therapy
JP7575104B2 (ja) ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖
US20210046159A1 (en) Il-1 antagonist and toxicity induced by cell therapy
CA3064597A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
KR20240004390A (ko) 림프종의 치료를 위한 car t 세포 요법 및 면역조정 화합물의 조합
JP2022554353A (ja) Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用
HK40074994A (en) Early intervention methods to prevent or ameliorate toxicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200318

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220324

R150 Certificate of patent or registration of utility model

Ref document number: 7048571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250